Hematology 2017: CME/MOC Tests
The CME/MOC Tests are divided into two subtests, one focused on malignant hematology content and one focused on non-malignant content. Successful completion of each test earns the participant 20 AMA PRA Category 1 Credits™. Participants claim CME credits and/or ABIM MOC points for each test individually and can take one or both tests, depending on their CME and MOC needs.
Hematology 2017: Malignant Test
The Hematology 2017: Malignant Test is a 25-question module worth 20 CME credits or ABIM MOC points.
These knowledge-based questions cover content from the 2017 ASH Education Program Sessions on:
• Acute Lymphocytic Leukemia: New Approaches in Management
• Acute Myeloid Leukemia: How Can We Improve Upon "Standard" Therapy?
• Ham-Wasserman Lecutre on AL Amyloidosis: From Molecular Mechanisms to Targeted Therapies
• Chronic Myeloid Leukemia: Where are We in the Current TKI Era?
• Controversies in Myeloma
• Dilemmas in Pediatric Hematological Malignancy
• Evolving Strategies in Aggressive B-Cell Lymphoma
• Hodgkin Lymphoma: New Insights, New Approaches
• Individualizing Therapy in Chronic Lymphocytic Leukemia
• Indolent Lymphoma: How Understanding Disease Biology is Influencing Clinical Decision-Making
• Myelodysplastic Syndrome: Understanding the Current Treatment Landscape
• Myeloproliferative Neoplasms: New Insights in the Current Treatment Paradigm
• Novel Therapeutics in Myeloma
• The Challenge of Primary and Secondary Central Nervous System Lymphoma
• The Expanding Role of Immunotherapy in Non-Hodgkin Lymphoma
• When Graft versus Tumor Fails: The Biology and Treatment of Relapse after Allogeneic Stem Cell Transplantation
Hematology 2017: Non-Malignant Test
The Hematology 2017: Non-Malignant Test is a 25-question module worth 20 CME credits or ABIM MOC points.
These knowledge-based questions cover content from the 2017 ASH Education Program Sessions on:• Bone Marrow Failure: Acquired
• Bone Marrow Failure: Inherited
• Common Clinical Questions in Cancer-Associated Venous Thromboembolism
• Common Hematologic Consults in Pregnancy
• Congenital and Acquired Neutropenia
• Controversies in Venous Thromboembolism: To Treat or Not to Treat
• It All Starts Here: Disorders of Primary Hemostasis
• Lessons Learned from Quality Improvement Initiatives in Sickle Cell Disease
• Emerging Issues in Clinical Care in Thalassemia
• Management of Sickle Cell Disease: Present and Future
• Practical Aspects of Acute and Chronic Pain Management in Sickle Cell Disease
• The Changing Landscape of Hemophilia Therapy
• Therapeutic Apheresis as an Immunomodulatory Tool
• Thrombocytopenia in Hospitalized Patients